Monthly Archives: February 2012

CORRECTING and REPLACING Leading Global Cell Therapy Organizations Support U.S. Department of Justice Appeal of Ruling …

Posted: Published on February 3rd, 2012

MINNEAPOLIS--(BUSINESS WIRE)-- Please replace the release dated January 23, 2012 with the following corrected version due to multiple revisions. The corrected release reads: LEADING GLOBAL CELL THERAPY ORGANIZATIONS SUPPORT U.S. DEPARTMENT OF JUSTICE APPEAL OF RULING ON DONOR COMPENSATION Coalition says PBSC donor compensation poses health risks to patients and donors A coalition of eight leading international health organizations today issued a statement supporting the U.S. Department of Justice’s appeal of the Ninth Circuit Court ruling that allows certain marrow donors to be compensated. Filed Jan. 17, the Justice Department’s appeal cites the potential for serious health risks to patients and donors if the ruling stands. Approximately 5,000 patients each year in the United States receive marrow transplants from unrelated donors to treat leukemia, lymphoma and a number of other diseases. The marrow is a source of stem cells that are critical to restoring the immune system for these patients. Two techniques are used to extract these stem cells. The first draws marrow directly from the donor’s hip bone and the second moves the stem cells out of the bone marrow and into the bloodstream using a stimulating hormone, and then collects peripheral blood stem cells (PBSCs) in a procedure … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on CORRECTING and REPLACING Leading Global Cell Therapy Organizations Support U.S. Department of Justice Appeal of Ruling …

Regenerative Medicine with Placenta Extracts and Stem Cell Therapies – Dr. Janethy Balakrishnan – Video

Posted: Published on February 3rd, 2012

24-08-2009 22:42 This is a preview of Regenerative Medicine with Placenta Extracts and Stem Cell Therapies by Dr. Janethy Balakrishnan at the 2008A4M Orlando Conference. Visit http://www.instatapes.com to purchase this lecture and many others on DiGiVision, video and slides synced. Also, visit http://www.worldhealth.net for the conference sponsor. Item #A5M-081W07 Visit link: Regenerative Medicine with Placenta Extracts and Stem Cell Therapies - Dr. Janethy Balakrishnan - Video … Continue reading

Comments Off on Regenerative Medicine with Placenta Extracts and Stem Cell Therapies – Dr. Janethy Balakrishnan – Video

Statement – Rx&D Applauds Government of Canada for Investing in Personalized Medicine

Posted: Published on February 3rd, 2012

OTTAWA , Feb. 1, 2012 /CNW/ - The following is a statement by Russell Williams , President of Canada's Research-Based Pharmaceutical Companies (Rx&D) on the announcement by the Government of Canada today to ensure that personalized medicine will allow for more effective treatments, thus supporting our Canadian health care system in a more sustainable way. "Canada's Research-Based Pharmaceutical Companies welcome this commitment by the Government of Canada to establish personalized medicine as the way to transform the delivery of health care to patients. "At Rx&D, we believe that providing the right medicine with the right dose to the right patient at the right time is crucial to improving health outcomes for Canadians. With the rise of chronic disease and an aging population, all governments are grappling with unprecedented demand for health care services. It is clear that we face a collective challenge to sustain and improve our health care system where traditional approaches are no longer efficient. "We commend the Government of Canada's commitment to engage in this work. Pharmaceutical innovation is a proven tool to help Canadians live longer, healthier, more productive lives. It is critical to the future productivity of our country, our workplaces, our communities and our … Continue reading

Comments Off on Statement – Rx&D Applauds Government of Canada for Investing in Personalized Medicine

CORRECTING and REPLACING Leading Global Cell Therapy Organizations Support U.S. Department of Justice Appeal of Ruling …

Posted: Published on February 3rd, 2012

MINNEAPOLIS--(BUSINESS WIRE)-- Please replace the release dated January 23, 2012 with the following corrected version due to multiple revisions. The corrected release reads: LEADING GLOBAL CELL THERAPY ORGANIZATIONS SUPPORT U.S. DEPARTMENT OF JUSTICE APPEAL OF RULING ON DONOR COMPENSATION Coalition says PBSC donor compensation poses health risks to patients and donors A coalition of eight leading international health organizations today issued a statement supporting the U.S. Department of Justice’s appeal of the Ninth Circuit Court ruling that allows certain marrow donors to be compensated. Filed Jan. 17, the Justice Department’s appeal cites the potential for serious health risks to patients and donors if the ruling stands. Approximately 5,000 patients each year in the United States receive marrow transplants from unrelated donors to treat leukemia, lymphoma and a number of other diseases. The marrow is a source of stem cells that are critical to restoring the immune system for these patients. Two techniques are used to extract these stem cells. The first draws marrow directly from the donor’s hip bone and the second moves the stem cells out of the bone marrow and into the bloodstream using a stimulating hormone, and then collects peripheral blood stem cells (PBSCs) in a procedure … Continue reading

Comments Off on CORRECTING and REPLACING Leading Global Cell Therapy Organizations Support U.S. Department of Justice Appeal of Ruling …

StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial

Posted: Published on February 3rd, 2012

NEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD), the most common form of AMD. AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million people worldwide are afflicted with the disease. There are no approved treatments for dry AMD. "With the approval of this trial, we have accomplished something truly unique in the stem cell field, which is the extension of clinical testing of our proprietary human neural stem cell platform to all three elements of the central nervous system: the brain, spinal cord and eye," said Martin McGlynn, President and CEO of StemCells, Inc. "The preclinical data supporting our IND is particularly compelling and we look forward to getting this trial underway." The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial

Stem Cell Treatment Paraplegic – Video

Posted: Published on February 3rd, 2012

31-01-2012 21:38 http://www.StemCellTreatment.org Jaime Chiriboga was an active adult and ended up in a motorcycle accident and left a quadriplegic. Before receiving stem cell treatment he could not move his limbs. After his stem cell therapy he was able to move his limbs and got back almost 100% sensitivity in his body! We are very happy with the results and even more important Jaime is happy with his results! Please look at our website for more information! Read more from the original source: Stem Cell Treatment Paraplegic - Video … Continue reading

Comments Off on Stem Cell Treatment Paraplegic – Video

Statement – Rx&D Applauds Government of Canada for Investing in Personalized Medicine

Posted: Published on February 2nd, 2012

OTTAWA , Feb. 1, 2012 /CNW/ - The following is a statement by Russell Williams , President of Canada's Research-Based Pharmaceutical Companies (Rx&D) on the announcement by the Government of Canada today to ensure that personalized medicine will allow for more effective treatments, thus supporting our Canadian health care system in a more sustainable way. "Canada's Research-Based Pharmaceutical Companies welcome this commitment by the Government of Canada to establish personalized medicine as the way to transform the delivery of health care to patients. "At Rx&D, we believe that providing the right medicine with the right dose to the right patient at the right time is crucial to improving health outcomes for Canadians. With the rise of chronic disease and an aging population, all governments are grappling with unprecedented demand for health care services. It is clear that we face a collective challenge to sustain and improve our health care system where traditional approaches are no longer efficient. "We commend the Government of Canada's commitment to engage in this work. Pharmaceutical innovation is a proven tool to help Canadians live longer, healthier, more productive lives. It is critical to the future productivity of our country, our workplaces, our communities and our … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Statement – Rx&D Applauds Government of Canada for Investing in Personalized Medicine

"For treatment we will have in the future" – Video

Posted: Published on February 2nd, 2012

20-01-2012 04:32 http://www.telethon.it - Pier Lorenzo Puri is a researcher at the Telethon Dulbecco Institute and works at the Santa Lucia Foundation in Rome. After a number of years as a researcher in the United States, he returned to Italy thanks to Telethon offering him a chance to create his own independent research laboratory in Italy in 2001.Having graduated as a medical doctor, Pier Lorenzo studies Duchenne muscular dystrophy and in particular the stage of the disease during which the patient's muscles try and mend themselves using particular stem cells. By intervening pharmacologically on this mechanism, Puri and his group aim to prolong for as long as possible this phase in which patients are still able to move autonomously and are above all more receptive to eventual treatment currently being studied. Read more: "For treatment we will have in the future" - Video … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on "For treatment we will have in the future" – Video

Workshop 2: Fundamentals of Genetic Testing Part I – Selena Martinez – Video

Posted: Published on February 2nd, 2012

02-11-2011 12:51 Selena shares her family's experience with Lynch syndrome. This workshop is part of a genomics curriculum for practicing healthcare providers developed by the Genomic Medicine Institute at El Camino Hospital, Genetic Alliance, and the National Coalition for Health Professional Education in Genetics. This workshop, the second in a 10-part series, covered genetic-testing technology; selecting appropriate genetic tests; ordering tests; pre- and post-test counseling; test costs; interpreting test results. Read more: Workshop 2: Fundamentals of Genetic Testing Part I - Selena Martinez - Video … Continue reading

Comments Off on Workshop 2: Fundamentals of Genetic Testing Part I – Selena Martinez – Video

Stem Cell Therapy in Neuromuscular Disease Research – Video

Posted: Published on February 2nd, 2012

31-01-2012 15:24 MDA Vice President of Research Sanjay Bidichandani explains the promising research being done in neuromuscular disease research using adult stem cells. Excerpt from: Stem Cell Therapy in Neuromuscular Disease Research - Video … Continue reading

Comments Off on Stem Cell Therapy in Neuromuscular Disease Research – Video